MetaCap

Enanta Pharmaceuticals (ENTA) vs Pyxis Oncology (PYXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enanta Pharmaceuticals (ENTA) has outperformed Pyxis Oncology (PYXS) over the past year, losing 40.1% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $216.5 million), about 1.0 times the size.

Enanta Pharmaceuticals converts more of its revenue into profit, with a net margin of -108.3% versus -574.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTA-40.14%PYXS-62.29%
+38%-23%-83%
Nov 21, 20251 yearNov 20, 2026
ENTA-89.88%PYXS-85.99%
+28%-36%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTA versus PYXS key metrics
MetricENTAPYXS
Share price$7.62$1.81
Market cap$222.19M$216.49M
1-day change-4.51%+7.74%
YTD return-51.68%+57.39%
1-year return-40.14%-62.29%
5-year return-91.71%-85.90%
EPS (TTM)$-2.35$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.00M$13.86M
Revenue growth (YoY)-3.56%-14.17%
Net income (latest FY)$-68.25M$-79.62M
Gross margin—82.77%
Operating margin-99.01%-609.18%
Net margin-108.33%-574.55%
52-week high$17.15$5.55
52-week low$7.56$1.03
Distance from 52-week high-55.57%-67.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+186.48%+354.14%
Average volume287.81K1.06M
Shares outstanding29.16M119.61M
Employees12056
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ENTA has outperformed PYXS by 22.2 percentage points over the past year.
  • Enanta Pharmaceuticals is more profitable, keeping -108.3 cents of every revenue dollar as net income versus -574.5 cents for Pyxis Oncology.
  • Enanta Pharmaceuticals grew revenue faster in its latest fiscal year (-3.56% vs -14.17%).

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

ENTA vs PYXS FAQ

Which is bigger, Enanta Pharmaceuticals or Pyxis Oncology?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $216.49M for Pyxis Oncology (PYXS).

Which stock has performed better over the past year, ENTA or PYXS?

ENTA returned -40.14% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Enanta Pharmaceuticals and Pyxis Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons